| Third Quarter Report 2011 |
September 30, 2011
Dear Shareholder,
Total sales for the third quarter 2011 were $60,400 compared to $6,400 for the 2010 third quarter.
During this quarter, we have entered into negotiations with GE for the license for our sushi peptide technology for the detection of endotoxin in pharmaceutical grade water and for potential clinical applications which include catheters, intravenous lines and ventilators.
We are continuing to work closely with Amgen on the development of a clinical assay for endotoxin for monitoring the treatment of Crohn's disease and ulcerative colitis.
Sincerely,
Michael G. Pepe, Ph.D.
Chairman, President and CEO
|
